Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Beer, Helen ^a   Southern, Kevin W ^b   Swift, Andrew C ^c  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; STEROID; GLUCOCORTICOID;

CLINICAL OUTCOME; CYSTIC FIBROSIS; DRUG EFFICACY; EPISTAXIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; NASAL DISCOMFORT; NOSE DISEASE; NOSE POLYP; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADULT; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADULT; BETAMETHASONE; CYSTIC FIBROSIS; GLUCOCORTICOIDS; HUMANS; NASAL POLYPS;

EID: 84886815088     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008253.pub3     Document Type: Review

References (23)

1. Hadfield PJ, Rowe-Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology 2000;38(2):63-5.
2. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Human mutation 2002;19(6):575-606. [PUBMED: 12007216].
3. Joint Formulary Committee. British National Formulary. 8th Edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2009.
4. Burgel PR, Cardell LO, Ueki IF, Nadel JA. Intranasal steroids decrease eosinophils but not mucous expression in nasal polyps. European Respiratory Journal 2004;24(4):594-600.
5. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
6. Fokkens W, Lund V, Mullol J. EPOS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology 2007;45(2):97-101.
7. Fokkens W, Lund V, Mullol J, European Position Paper on Rhinosinusitis and Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology. Supplement 2007;20:1-136.
8. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54. [DOI: 10.1136/thorax.55.11.946].
9. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. International Journal of Epidemiology 1999;28(4):717-22.
10. Henriksson G, Westrin KM, Karpati F, Wikström AC, Stierna P, Hjelte L. Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage fluid analysis. Chest 2002;121(1):40-7.
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
12. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
13. Hopkins C, Gillet S, Slack R, Lund V, Browne J. Psychometric validity of the 22-item Sinonasal Outcome Test. Clinical Otolaryngology 2009;34(5):447-54(8).
14. Kim SSY, Wong ECK, Kalish L, Craig JC. Topical steroids for nasal polyps. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006549].
15. Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. Archives of Otolaryngology - Head and Neck Surgery 1998;124(5):513-8.
16. Mackay IS, Lund VJ. Imaging and staging. In: Mygind N, Lildholdt T editor(s). In Nasal Polyposis: An Inflammatory Disease and Its Treatment. Copenhagen: Munksgaard, 1997:137-44.
17. Patiar S, Reece P. Oral steroids for nasal polyps. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005232.pub2].
18. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
19. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
20. Robertson JM, Friedman EM, Rubin BK. Nasal and sinus disease in cystic fibrosis. Paediatric Respiratory Review 2008;9(3):213-9. [PUBMED: 18694713].
21. Roby BB, McNamara J, Finkelstein M, Sidman J. Sinus surgery in cystic fibrosis patients: comparison of sinus and lower airway cultures. International Journal of Pediatric Otorhinolaryngology 2008;72(9):1365-9.
22. Southern KW. Cystic fibrosis and formes frustes of CFTR-related disease. Respiration 2007;74(3):241-51. [PUBMED: 17534127].
23. Beer H, Southern KW, Swift AC. Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD008253.pub2].